IDIOPATHIC PULMONARY FIBROSIS. ADVANCES IN DIAGNOSTIC TOOLS AND DISEASE MANAGEMENT

1. Definition of IPF
2. Epidemiology and Risk Factors of IPF
3. Acute Exacerbation of IPF
4. Pathogenesis of IPF
5. Specific Serum Markers of IPF
6. High-Resolution Computed Tomography of Honeycombing and IPF/UIP
7. Pathology of IPF
8. Differential Diagnosis of IPF
9. Pharmacotherapy of IPF Using Antifibrotic Compounds
10. Pharmacotherapy of IPF (Corticosteroids, Immunosuppressants, Etc.)
11. Non-pharmacological Therapy for IPF
12. Pharmacotherapy of Acute Exacerbation of IPF (Corticosteroids, Immunosuppressants, and Direct Hemoperfusion with Polymyxin)
13. Combined Pulmonary Fibrosis and Emphysema (CPFE)
14. Common Pathways in IPF and Lung Cancer
15. Acute Exacerbation of Interstitial Pneumonia After Pulmonary Resection for Lung Cancer

From epidemiology and pathogenesis to disease management, this book reviews our current understanding of and provides up-to-date information of Idiopathic Pulmonary Fibrosis (IPF). A subtype of Idiopathic Interstitial Pneumonias (IIP), IPF is one of the most elusive and intractable respiratory disease to date and its triggering factors remain unclear. However, new developments such as serum markers that are highly specific to IPF (i.e. KL-6, SP-A, and SP-D), the establishment of systematic diagnostic imaging (HRCT) and accumulated reports of treatment using an antifibrotic agent (pirfenidone) are slowly improving our understanding of the disease. Edited by an established authority in the field and written by experts, this book will be valuable to not only to beginning learners but also to physicians, instructors and researchers whose work involves IIPs. With each chapter exploring critical questions, with unresolved issues and future prospects, the book offers a valuable resource for understanding issues such as the newly proposed entity of interstitial pneumonia with emphysema (combined pulmonary fibrosis and emphysema: CPFE) and the mechanism of how so many IIP sufferers develop lung cancer.

Features
• Introducing new developments such as serum makers that are highly specific to IPF, the establishment of systematic diagnosis imaging and antifibrotic agent
• Each chapter addresses key issues under discussion and provides perspective on future developments in the field
• Valuable source for beginning learners to physicians, instructors and researchers whose work involves IIPs

Authors
• Hiroyuki Nakamura, MD, PhD.. Department of Respiratory Medicine,. Tokyo Medical University Ibaraki Medical Center, Japan
• Kazutetsu Aoshiba, MD, PhD.. Department of Respiratory Medicine,. Tokyo Medical University Ibaraki Medical Center, Japan